Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.

PloS one - 1 Jan 2018

Wei Lai, Wedemeyer Heiner, Liaw Yun-Fan, Chan Henry Lik-Yuen, Piratvisuth Teerha, Marcellin Patrick, Jia Jidong, Tan Deming, Chow Wan-Cheng, Brunetto Maurizia R, Diago Moisés, Gurel Selim, Morozov Viacheslav, He Hua, Zhu Yonghong, Wat Cynthia, Surujbally Bernadette, Thompson Alexander J

Abstract excerpt

BACKGROUND & AIMS: It has yet to be firmly established whether host IFNL3 (IL28B) genotype influences interferon responsiveness in patients with chronic hepatitis B. We investigated associations between single-nucleotide polymorphisms (SNPs) in the IFNL3 region and response to peginterferon alfa-2a in 701 patients enrolled in three large, randomized, international studies. METHODS: Responses were defined as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Source

Open in PubMed Open full text

Identifiers

PMID: 30016335
DOI: 10.1371/journal.pone.0199198
PMCID: PMC6049926

Genes

IFNL3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.PMID 30016335Read ↗

IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.Semantic proximity Read ↗

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.Semantic proximity Read ↗

Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?Semantic proximity Read ↗

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.Semantic proximity Read ↗

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.Semantic proximity Read ↗

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.Semantic proximity Read ↗

Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?Semantic proximity Read ↗

IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan.Semantic proximity Read ↗

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.Semantic proximity Read ↗

Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Semantic proximity Read ↗

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.